MA52412A - Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie - Google Patents
Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foieInfo
- Publication number
- MA52412A MA52412A MA052412A MA52412A MA52412A MA 52412 A MA52412 A MA 52412A MA 052412 A MA052412 A MA 052412A MA 52412 A MA52412 A MA 52412A MA 52412 A MA52412 A MA 52412A
- Authority
- MA
- Morocco
- Prior art keywords
- prophylaxis
- derivatives
- treatment
- new
- liver cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018077501 | 2018-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52412A true MA52412A (fr) | 2021-06-02 |
Family
ID=65685310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052412A MA52412A (fr) | 2018-02-28 | 2019-02-26 | Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3758707A1 (fr) |
| JP (1) | JP7089596B2 (fr) |
| KR (1) | KR20200128414A (fr) |
| CN (1) | CN111801100B (fr) |
| AR (1) | AR114419A1 (fr) |
| AU (1) | AU2019228654A1 (fr) |
| BR (1) | BR112020016509A2 (fr) |
| CA (1) | CA3091950A1 (fr) |
| CL (1) | CL2020002139A1 (fr) |
| CO (1) | CO2020010306A2 (fr) |
| IL (1) | IL276817A (fr) |
| MA (1) | MA52412A (fr) |
| MX (1) | MX2020008746A (fr) |
| PE (1) | PE20211456A1 (fr) |
| PH (1) | PH12020551343A1 (fr) |
| RU (1) | RU2020131012A (fr) |
| SG (1) | SG11202008291XA (fr) |
| TW (1) | TW202003518A (fr) |
| WO (1) | WO2019166432A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| KR102409595B1 (ko) | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 |
| CN112420196A (zh) * | 2020-11-20 | 2021-02-26 | 长沙市弘源心血管健康研究院 | 急性心肌梗死患者5年内生存率的预测方法和系统 |
| WO2024013205A1 (fr) * | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Composés de phosphorylpurinone pour le traitement du cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| EP2364314B1 (fr) | 2008-12-09 | 2014-03-12 | Gilead Sciences, Inc. | Modulateurs de récepteurs de type toll (tlr) |
| BRPI1010937A2 (pt) * | 2009-05-21 | 2019-09-24 | Astrazeneca Ab | composto, uso de um composto, e, método para tratar câncer |
| JP5694345B2 (ja) * | 2009-10-22 | 2015-04-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体の調節因子 |
| WO2011079016A1 (fr) * | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Méthodes de traitement d'une infection par le vhb et le vhc |
| AU2011270701B2 (en) | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| WO2012021834A1 (fr) * | 2010-08-13 | 2012-02-16 | Baylor Research Institute | Nouveaux adjuvants pour vaccins basés sur le ciblage d'adjuvants pour anticorps directement sur les cellules présentant des antigènes |
| KR20180003612A (ko) | 2015-05-08 | 2018-01-09 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체 |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| PT3504210T (pt) * | 2016-08-29 | 2021-04-19 | H Hoffnabb La Roche Ag | Compostos de sulfonimidoílpurinona 7-substituídos para o tratamento e profilaxia de infeção por vírus |
| KR102497701B1 (ko) * | 2016-09-13 | 2023-02-09 | 에프. 호프만-라 로슈 아게 | Tlr7 작용제 및 hbv 캡시드 조립 억제제의 병용 치료 |
-
2019
- 2019-02-26 AU AU2019228654A patent/AU2019228654A1/en not_active Abandoned
- 2019-02-26 CA CA3091950A patent/CA3091950A1/fr active Pending
- 2019-02-26 EP EP19708981.6A patent/EP3758707A1/fr active Pending
- 2019-02-26 KR KR1020207027935A patent/KR20200128414A/ko unknown
- 2019-02-26 MA MA052412A patent/MA52412A/fr unknown
- 2019-02-26 WO PCT/EP2019/054729 patent/WO2019166432A1/fr unknown
- 2019-02-26 CN CN201980015912.7A patent/CN111801100B/zh active Active
- 2019-02-26 MX MX2020008746A patent/MX2020008746A/es unknown
- 2019-02-26 JP JP2020544794A patent/JP7089596B2/ja active Active
- 2019-02-26 RU RU2020131012A patent/RU2020131012A/ru unknown
- 2019-02-26 BR BR112020016509-3A patent/BR112020016509A2/pt not_active Application Discontinuation
- 2019-02-26 SG SG11202008291XA patent/SG11202008291XA/en unknown
- 2019-02-26 PE PE2020001228A patent/PE20211456A1/es unknown
- 2019-02-27 TW TW108106752A patent/TW202003518A/zh unknown
- 2019-02-28 AR ARP190100505A patent/AR114419A1/es unknown
-
2020
- 2020-08-19 CL CL2020002139A patent/CL2020002139A1/es unknown
- 2020-08-19 IL IL276817A patent/IL276817A/en unknown
- 2020-08-21 CO CONC2020/0010306A patent/CO2020010306A2/es unknown
- 2020-08-27 PH PH12020551343A patent/PH12020551343A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL276817A (en) | 2020-10-29 |
| RU2020131012A (ru) | 2022-03-28 |
| CN111801100B (zh) | 2023-10-24 |
| CO2020010306A2 (es) | 2020-08-31 |
| AR114419A1 (es) | 2020-09-02 |
| KR20200128414A (ko) | 2020-11-12 |
| TW202003518A (zh) | 2020-01-16 |
| CN111801100A (zh) | 2020-10-20 |
| MX2020008746A (es) | 2020-09-28 |
| EP3758707A1 (fr) | 2021-01-06 |
| WO2019166432A1 (fr) | 2019-09-06 |
| CL2020002139A1 (es) | 2021-01-04 |
| JP7089596B2 (ja) | 2022-06-22 |
| PH12020551343A1 (en) | 2021-06-21 |
| JP2021514972A (ja) | 2021-06-17 |
| CA3091950A1 (fr) | 2019-09-06 |
| AU2019228654A1 (en) | 2020-09-03 |
| PE20211456A1 (es) | 2021-08-05 |
| BR112020016509A2 (pt) | 2020-12-15 |
| SG11202008291XA (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52412A (fr) | Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA55959A (fr) | Dosage d'inhibiteur de kras pour le traitement de cancers | |
| MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
| MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
| MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| MA42136A (fr) | Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38 | |
| MA53558A (fr) | Compositions et procédés pour le traitement d'infections virales | |
| MA55560A (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA52861A (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
| MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation | |
| MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| MA52415A (fr) | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines |